Physician profile
Muhammad Khalid
NPI 1679536338
$3,306.85
in general payments reported to CMS, 2019-2025
27 companies · $462 in 2025
The $462 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $852 · 2020: $210 · 2021: $605 · 2022: $194 · 2023: $448 · 2024: $537 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $801.52 | 2019-2025 | |
| Abbott Laboratories | $644.75 | 2019-2024 | Portico, Gallant, Assurity |
| Medtronic Vascular, INC. | $483.67 | 2019 | |
| Amgen INC. | $235.99 | 2019-2025 | Repatha |
| Medtronic, INC. | $234.11 | 2021 | |
| Emd Serono, INC. | $218.50 | 2023-2025 | Mavenclad, Mavenclad |
| E.R. Squibb & Sons, L.L.C. | $125.66 | 2019-2024 | Camzyos |
| Argenx US, INC. | $103.44 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Edwards Lifesciences Corporation | $48.08 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Vifor Pharma, INC. | $47.35 | 2022-2023 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.26 | 2023-2025 | Jardiance |
| Tg Therapeutics, INC. | $38.49 | 2024 | |
| Merck Sharp & Dohme LLC | $31.94 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $25.74 | 2023 | Evkeeza |
| Livanova USA, INC. | $24.15 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $21.93 | 2024 | Arcalyst |
| Lundbeck LLC | $21.02 | 2025 | Vyepti |
| Amryt Pharma Holdings LTD | $19.74 | 2021 | |
| Pfizer INC. | $19.47 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.60 | 2024 | Ultomiris |
| Irhythm Technologies, INC. | $16.76 | 2023 | Zio Xt Patch |
| Athena Bioscience, LLC | $15.63 | 2023 | Nexiclon Xr |
| Abiomed | $15.19 | 2020 | |
| Abbvie INC. | $14.22 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $14.12 | 2025 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $12.97 | 2019 | |
| Esperion Therapeutics, INC. | $12.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.